[Form 4] Oncology Institute, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Oncology Institute, Inc. (TOI) director equity grant reported

A director of Oncology Institute, Inc. reported receiving new equity awards in the form of restricted stock units (RSUs). On 11/20/2025, the reporting person acquired 46,296 shares of common stock through RSUs that will vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service. On the same date, the director also acquired 37,037 fully vested RSUs, with no cash price per share reported for either grant. Following these transactions, the director beneficially owns 333,539 shares of TOI common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ling Gabriel

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE OF HOPE

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CA 90703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		A		46,296(1)	A	$0	296,502	D
Common Stock	11/20/2025		A		37,037(2)	A	$0	333,539	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date.

2. . Represents restricted stock units that were fully vested upon grant.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Gabriel Ling	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for Oncology Institute, Inc. (TOI)?

A director of Oncology Institute, Inc. (TOI) reported acquiring new restricted stock units and common stock on 11/20/2025, as disclosed on a Form 4.

How many TOI shares did the director acquire in the latest Form 4?

The director acquired 46,296 shares of TOI common stock via RSUs vesting at the 2026 annual meeting and 37,037 fully vested RSUs, both at a reported price of $0 per share.

What are the vesting terms of the new restricted stock units for TOI’s director?

One RSU grant of 46,296 shares will vest in full on TOI’s 2026 annual stockholder meeting date, subject to the director’s continued service with the company.

Were any of the TOI restricted stock units fully vested on grant?

Yes. A separate grant of 37,037 restricted stock units was reported as fully vested upon grant on 11/20/2025.

What is the director’s total beneficial ownership of TOI shares after these grants?

After the reported transactions, the director beneficially owns 333,539 shares of Oncology Institute, Inc. common stock in direct ownership form.

At what price were the TOI restricted stock units granted to the director?

Both RSU-related acquisitions of 46,296 and 37,037 TOI shares were reported at a transaction price of $0 per share on the Form 4.

What role does the reporting person hold at Oncology Institute, Inc. (TOI)?

The reporting person is identified as a Director of Oncology Institute, Inc. (TOI) on the Form 4.